about-me variable
BioReperia invites you to their event

Accurate evaluation of tumor dissemination and metastasis in only 5-days using ZTX models

About this event


This session

Part 3

In this live webinar the co-founder and CTO of BioReperia Dr Jensen will talk about how targeting tumor dissemination and metastasis is made possible using ZTX models, and why it is important to consider this as a part of early anticancer drug discovery and development. The rapid development of the zebrafish embryo and therefore vascularization of the implanted tumors, makes ZTX models the perfect in-vivo tool for identifying and studying local invasion, vascular dissemination, and metastasis of primary tumors, at single-cell resolution, and over time, in a living organism. Recent data coupling dissemination and metastasis in ZTX models created from patient tumor biopsies or PDX models to the actual lymphatic dissemination and metastasis of the patients demonstrated that the ZTX-models are astoundingly accurate models of this process.

Join this live session to find out more about how tumor dissemination and metastasis can be measured with BioReperias ZTX Oncoleads platform.


Lasse Jensen, PhD

BioReperia, co-founder and CTO

Something smells fishy: Removing doubts – Zebrafish an exceptional translational in-vivo tool for drug development and personalized medicine in cancer

Zebrafish has long been used by academic researchers to reveal molecular mechanisms involved in disease development and treatment. As a tool for cancer research, tumors transplanted to zebrafish embryos, so-called zebrafish tumor xenograft (ZTX) models, are rapidly gaining popularity. This remarkable and diverse in vivo platform has recently been revealed to have diagnostic potential by predicting patient treatment outcome and can therefore be used for precision medicine within oncology. The ZTX platform is also useful for pre-clinical drug development including lead optimization, target validation, immune-oncology, patient stratification, companion diagnostics, and so much more. In the five webinars comprising this webinar series, BioReperia will introduce the latest research based on ZTX models and their applications within drug development and personalized medicine. We will highlight the benefits and potential pitfalls of using ZTX models, and how they can synergize with other cancer model systems or diagnostic tests.

During these five consecutive months from September to January BioReperia is hosting a webinar series in five parts. Please join our webinars by registering for each individual session here, or when they are published on our LinkedIn page and website.

Webinar language: English


Part 1: 21 September 5 pm CEST

Part 2: 19 October 5 pm CEST

Part 3: 16 November 5 pm CEST

Part 4: TBA

Part 5: TBA

Hosted by

  • Team member
    MV T
    Malin Vildevall MSL @ BioReperia

  • Guest speaker
    Lasse Jensen Co-founder, CTO @ BioReperia


We are a contract research organization (CRO) that increase the speed for your pre-clinical drug discovery.